Physician profile
Erin Mcgee
NPI 1548546336
$2,696.91
in general payments reported to CMS, 2019-2025
22 companies · $822 in 2025
The $822 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.91 · 2022: $301 · 2023: $1,100 · 2024: $456 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.64 |
| Education | $268.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $426.29 | 2022-2023 | Tremfya, Remicade, Simponi |
| Incyte Corporation | $315.26 | 2022-2025 | Opzelura, Opzelura, Iclusig |
| Arcutis Biotherapeutics, INC. | $287.16 | 2023-2025 | Zoryve |
| Abbvie INC. | $249.59 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $213.72 | 2022-2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $184.34 | 2023-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $131.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $130.92 | 2022-2025 | |
| Dermavant Sciences, INC. | $124.84 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $103.56 | 2022 | |
| Amgen INC. | $100.66 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $83.88 | 2024-2025 | Nemluvio, Aklief |
| Verrica Pharmaceuticals INC. | $75.56 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $56.11 | 2021-2022 | |
| Almirall LLC | $56.02 | 2024-2025 | Klisyri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.70 | 2025 | |
| Leo Pharma INC. | $24.87 | 2025 | Adbry |
| Lilly USA, LLC | $22.89 | 2023 | Olumiant, Taltz |
| Medimetriks Pharmaceuticals, INC. | $21.22 | 2025 | Neo-Synalar, Clindacin Etz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.18 | 2025 | Cabtreo |
| Botanix Sb INC | $19.39 | 2025 | Sofdra |
| Journey Medical Corporation | $17.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.